Last reviewed · How we verify

NCT06097585

Gliflozins on HF in Regurgitant Rheumatic Heart

Status unknown Last updated 30 October 2023
What this trial tests

trial testing SGLT2 inhibitor in Rheumatic Heart Disease in 150 participants. Status unknown.

Timeline
1 December 2023
Primary endpoint
1 December 2024
1 April 2025

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment150
Start date1 December 2023
Primary completion1 December 2024
Estimated completion1 April 2025

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

18 and older, any sex, with Rheumatic Heart Disease or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this trial is to detect impact of Gliflozin on patients with heart failure due to reurgitant rheumatic valve disease

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease
    Morel O, Mai A, Zühlke L, Jouven X, et al · · 2026

Verify or expand the search:

Other trials of SGLT2 inhibitor

Trials testing the same drug.

Other recruiting trials for Rheumatic Heart Disease

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06097585.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing